Analyzing Nanovibronix (NASDAQ:FEED) & ReShape Lifesciences (OTCMKTS:RSLSD)

ReShape Lifesciences (OTCMKTS:RSLSD) and Nanovibronix (NASDAQ:FEED) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, dividends and risk.

Volatility & Risk

ReShape Lifesciences has a beta of 2.03, suggesting that its share price is 103% more volatile than the S&P 500. Comparatively, Nanovibronix has a beta of 2.21, suggesting that its share price is 121% more volatile than the S&P 500.

Insider and Institutional Ownership

16.4% of Nanovibronix shares are held by institutional investors. 1.4% of Nanovibronix shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for ReShape Lifesciences and Nanovibronix, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ReShape Lifesciences	0	0	0	0	0.00
Nanovibronix	1	0	0	0	1.00

Given ReShape Lifesciences’ higher probable upside, equities research analysts plainly believe ReShape Lifesciences is more favorable than Nanovibronix.

Profitability

This table compares ReShape Lifesciences and Nanovibronix’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ReShape Lifesciences	-668.58%	-163.22%	-52.10%
Nanovibronix	-275.12%	-24.78%	-19.24%

Earnings and Valuation

This table compares ReShape Lifesciences and Nanovibronix”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ReShape Lifesciences	$610,000.00	0.00	-$81.15 million	N/A	N/A
Nanovibronix	$2.56 million	0.89	-$3.70 million	($41.74)	-0.05

Nanovibronix has higher revenue and earnings than ReShape Lifesciences.

Summary

Nanovibronix beats ReShape Lifesciences on 9 of the 10 factors compared between the two stocks.

About ReShape Lifesciences

ReShape Lifesciences Inc., a medical device company, focuses on the design, development, and commercialization of technology to treat obesity, metabolic diseases, and other gastrointestinal disorders. The company's product portfolio includes ReShape vBloc, a therapy that enables patients to feel full and eat less by intermittently blocking hunger signals on the vagus nerve; ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without permanently changing patient anatomy; and Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in October 2017. ReShape Lifesciences Inc. was founded in 2002 and is headquartered in San Clemente, California.

About Nanovibronix

NanoVibronix Inc. is a medical device company that is focused on creating medical products utilizing its proprietary low-intensity, surface acoustic wave technology. … NanoVibronix’ catheter-based products include the UroShield™ and NG-Shield™ devices that are both CE mark certified.